6990 — Sichuan Kelun-Biotech Biopharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00- HK$107.95bn
- HK$102.91bn
- CNY2.06bn
Annual balance sheet for Sichuan Kelun-Biotech Biopharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 81.8 | 93 | 2,488 | 3,069 | 4,472 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 70.6 | 104 | 124 | 244 | 291 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 298 | 332 | 2,807 | 3,493 | 5,149 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 514 | 658 | 701 | 773 | 769 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 813 | 993 | 3,510 | 4,268 | 5,989 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3,445 | 4,167 | 1,110 | 810 | 1,004 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3,457 | 4,219 | 1,180 | 959 | 1,121 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -2,644 | -3,226 | 2,329 | 3,309 | 4,867 |
| Total Liabilities & Shareholders' Equity | 813 | 993 | 3,510 | 4,268 | 5,989 |
| Total Common Shares Outstanding |